Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy

NEXT STORY
Kintai Therapeutics Announces the Appointment of Mary Szela, Industry Veteran with Over 30 Years of Executive Experience, to its Board of Directors
PREV STORY
RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury

Analyses to Be Presented in Oral and Poster Sessions at The 23rd International Conference on ...

author_avatar
NASDAQ Market News

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration

author_avatar
NASDAQ Market News

CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19

author_avatar
NASDAQ Market News